论文部分内容阅读
为探讨生后常规应用苯巴比妥钠对早产儿脑室周围-脑室内出血的预防价值,将112例早产儿随机分为苯巴比妥钠预防组和对照组,对两组脑室周围-脑室内出血的发生率及重度出血发生率进行比较。结果显示苯巴比妥钠预防组和对照组颅内出血发生率分别为52·0%和56·4%(χ2=0·221,P=0·638),重度出血发生率分别为4·0%和17·7%(χ2=5·09,P=0·024)。产后注射苯巴比妥钠虽不能使早产儿脑室周围-脑室内出血总的发生率降低,但可减少重度出血的发生及减少轻度出血转化为重度出血,因而有较重要的临床实用价值。
In order to explore the value of routine use of phenobarbital in premature infants after ventricular perimetrioventricular hemorrhage prevention value, 112 cases of premature infants were randomly divided into prevention and control group, phenobarbital, ventricular peri-ventricular hemorrhage The incidence and severity of bleeding were compared. The results showed that the incidence of intracranial hemorrhage in the phenobarbital sodium prevention group and the control group were 52.0% and 56.4% (χ2 = 0 · 221, P = 0.638), and the rates of severe bleeding were 4.0 % And 17.7% (χ2 = 5.90, P = 0.024). Although postpartum phenobarbital sodium can not reduce the incidence of periventricular - intraventricular hemorrhage in premature infants, it can reduce the incidence of severe bleeding and reduce the mild bleeding into severe bleeding, which has more important clinical value.